Oryzon Genomics SA (ES:ORY)
BME:ORY
Want to see ES:ORY full AI Analyst Report?
ORY Stock Chart & Stats
€3.22
€0.02(1.34%)
At close: 4:00 PM EST
€3.22
€0.02(1.34%)
Day’s Range― - ―
52-Week Range€2.56 - €4.02
Previous CloseN/A
Volume6.85K
Average Volume (3M)1.68M
Market Cap
€242.71M
Enterprise Value€232.91M
Total Cash (Recent Filing)€31.11M
Total Debt (Recent Filing)€13.73M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Jul 29, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding79,887,700
10 Day Avg. Volume2,474,153
30 Day Avg. Volume1,678,358
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.40Price Target Upside98.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.12
Revenue Forecast (FY)€8.20M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA stronger equity base and low debt provide durable financial flexibility for a clinical-stage biotech. That position reduces short-term insolvency risk, supports continued R&D spending or partnering negotiations, and lessens immediate reliance on hostile or dilutive financing.
Focused Epigenetics PipelineA targeted pipeline in epigenetic therapies (LSD1 inhibitors) concentrates technical expertise on high-value oncology and CNS indications. That focus can create differentiated science, clearer partnering/licensing pathways, and a durable product development thesis if clinical progress continues.
Gross Margin PotentialWhen revenue occurs, gross profit has been strong, indicating potential for attractive product-level margins. If the company secures recurring commercial or licensing revenue, those margins could scale; long-term profitability then hinges on containing operating costs and achieving steady sales.
Bears Say
Persistent Cash BurnChronic negative operating and free cash flow creates an ongoing need for external funding to sustain development. Over months this forces reliance on equity raises or deals, increasing dilution risk and potentially constraining strategic choices or timelines if financing terms tighten.
Consistent Net LossesRepeated operating and net losses mean capital is not yet generating returns, eroding retained equity and limiting reinvestment capacity. Over time this pressures management to secure partnerships or additional funding, and delays the structural shift to self-sustaining operations.
Volatile Revenue ProfileIrregular, episodic revenue—including multiple zero-revenue years—impairs reliable forecasting and undermines operational planning. Structural dependence on one-off or milestone payments increases business risk and complicates long-term investment in commercial infrastructure.
Oryzon Genomics SA News
ORY FAQ
What was Oryzon Genomics SA’s price range in the past 12 months?
Oryzon Genomics SA lowest stock price was €2.56 and its highest was €4.02 in the past 12 months.
What is Oryzon Genomics SA’s market cap?
Oryzon Genomics SA’s market cap is €242.71M.
When is Oryzon Genomics SA’s upcoming earnings report date?
Oryzon Genomics SA’s upcoming earnings report date is Jul 29, 2026 which is in 56 days.
How were Oryzon Genomics SA’s earnings last quarter?
Oryzon Genomics SA released its earnings results on May 14, 2026. The company reported -€0.017 earnings per share for the quarter, the consensus estimate of -€0.017 by €0.
Is Oryzon Genomics SA overvalued?
According to Wall Street analysts Oryzon Genomics SA’s price is currently Undervalued.
Does Oryzon Genomics SA pay dividends?
Oryzon Genomics SA does not currently pay dividends.
What is Oryzon Genomics SA’s EPS estimate?
Oryzon Genomics SA’s EPS estimate is -0.06.
How many shares outstanding does Oryzon Genomics SA have?
Oryzon Genomics SA has 79,887,700 shares outstanding.
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Oryzon Genomics SA reported an EPS of -€0.017 in its last earnings report, expectations of -€0.017. Following the earnings report the stock price went up 2.253%.
Which hedge fund is a major shareholder of Oryzon Genomics SA?
Currently, no hedge funds are holding shares in ES:ORY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
ORY Stock 12 Month Forecast
Average Price Target
€6.40
▲(98.71% Upside)
Technical Analysis
Options Prices
Currently, No data available
---